News & Publications

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

  • KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)

  • KemPharm Reports Third Quarter 2022 Results

  • KemPharm to Report Third Quarter 2022 Financial Results

  • KemPharm Supports Niemann-Pick Awareness Month During October and Global Niemann-Pick Awareness Day on October 19th

  • KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)

  • KemPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference

  • KemPharm Reports Second Quarter 2022 Financial Results and Corporate Updates

  • KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications

  • KemPharm to Report Second Quarter 2022 Financial Results

  • KemPharm to Present at the Canaccord Genuity 42nd Annual Growth Conference

  • KemPharm to Participate in the 2022 Joint NNPDF-INPDA Conference and Meeting

  • KemPharm Announces Research Affirming Serdexmethylphenidate’s Lower Potential for Abuse Featured in Peer-Reviewed Publication, Current Medical Research & Opinion